Sage Therapeutics expects cash, equivalents and securities sufficient into 2026

Sage expects that, based on its current estimates, its current cash, cash equivalents and marketable securities, along with anticipated funding from ongoing collaborations, collaboration revenue from sales of ZURZUVAE, and a potential milestone payment of $75.0M from Biogen for the first commercial sale of ZURZUVAE for the treatment of women with PPD, will support operations into 2026. Additionally, Sage underwent a strategic reorganization and pipeline reprioritization in August 2023. The company expects annualized net savings of approximately $240M, of which 60% is related to R&D. The annualized net savings include $100M related to the workforce reduction.